Entropy Technologies’s Viking Therapeutics VKTX Stock Holding History

Entropy Technologies’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,300	Closed	-$507K	–	1179
2025 Q3	$507K	Buy	19,300 +7,241	+60%	+$216K	0.04%	513
2025 Q2	$320K	Buy	+12,059	New	+$317K	0.03%	596
2024 Q3	–	Sell	-14,246	Closed	-$755K	–	939
2024 Q2	$755K	Buy	+14,246	New	+$934K	0.08%	293

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Entropy Technologies's VKTX Position: Q4 2025 in Review

Entropy Technologies sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 19,300 shares — an estimated $507K sold.

Entropy Technologies first reported a position in VKTX in Q2 2024 and held it in 3 quarters. The position peaked at $755K in Q2 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Entropy Technologies reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Entropy Technologies sold 19,300 Viking Therapeutics shares in Q4 2025, an estimated $507K.
Entropy Technologies first reported a position in Viking Therapeutics in Q2 2024 and held it in 3 quarters.
Entropy Technologies's Viking Therapeutics position peaked at $755K in Q2 2024.
426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Entropy Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.